Response to neoadjuvant chemoradiotherapy in rectal cancer is associated with RAS/AKT pathway dysregulation and high tumour mutational burden

Joanne D Stockton, Louise Tee, Celina Whalley, Jonathan James, Mark Dilworth, Rachel Wheat, Thomas Nieto, Ian Geh, Andrew D Beggs
doi: https://doi.org/10.1101/2020.02.01.20019794

Article usage

Article usage: February 2020 to June 2025

AbstractFullPdf
Feb 2020283069
Mar 2020118069
Apr 202061020
May 202073030
Jun 202031014
Jul 202031016
Aug 202034018
Sep 202030010
Oct 202025032
Nov 202045118
Dec 20202545
Jan 202137211
Feb 20215436
Mar 202146414
Apr 20219724
May 202189516
Jun 202176519
Jul 20214189
Aug 20212456
Sep 202128513
Oct 202134720
Nov 202117811
Dec 20211723
Jan 202222127
Feb 20223063
Mar 20221536
Apr 20221756
May 202211210
Jun 20221112
Jul 20221415
Aug 20221627
Sep 20223735
Oct 202227110
Nov 202213110
Dec 20222068
Jan 20233024
Feb 20231556
Mar 20232544
Apr 202332127
May 202310213
Jun 20231353
Jul 2023705
Aug 202317138
Sep 20231253
Oct 2023816
Nov 20233721
Dec 2023803
Jan 2024904
Feb 2024841
Mar 202419110
Apr 20241375
May 20241123
Jun 202420126
Jul 2024836
Aug 2024105
Sep 20243047
Oct 2024857
Nov 2024968
Dec 20242317
Jan 20251916
Feb 202593112
Mar 202518367
Apr 20252098
May 20251077
Jun 2025240
Back to top
Posted February 04, 2020.
Download PDF
Data/Code
Email
Response to neoadjuvant chemoradiotherapy in rectal cancer is associated with RAS/AKT pathway dysregulation and high tumour mutational burden
Joanne D Stockton, Louise Tee, Celina Whalley, Jonathan James, Mark Dilworth, Rachel Wheat, Thomas Nieto, Ian Geh, Andrew D Beggs
medRxiv 2020.02.01.20019794; doi: https://doi.org/10.1101/2020.02.01.20019794
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area